- Previous Close
367.90 - Open
364.10 - Bid --
- Ask --
- Day's Range
364.10 - 372.85 - 52 Week Range
330.85 - 537.70 - Volume
120,598 - Avg. Volume
675,670 - Market Cap (intraday)
21.718B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
21.73 - EPS (TTM)
17.02 - Earnings Date Feb 4, 2025 - Feb 8, 2025
- Forward Dividend & Yield 5.00 (1.35%)
- Ex-Dividend Date Feb 16, 2024
- 1y Target Est
434.00
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company offers active pharmaceutical ingredients (API), such as ibuprofen lysinate and ibuprofen sodium; and other APIs, including metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole, gabapentin, levetiracetam, paracetamol, etc. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited provides specialty industrial chemicals comprising ethyl acetate, iso butyl benzene, acetyl chloride, para amino phenol, and mono chloro acetic acid to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.
www.iolcp.com2,777
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: IOLCP.NS
View MorePerformance Overview: IOLCP.NS
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IOLCP.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IOLCP.NS
View MoreValuation Measures
Market Cap
21.72B
Enterprise Value
21.41B
Trailing P/E
21.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.06
Price/Book (mrq)
1.31
Enterprise Value/Revenue
1.05
Enterprise Value/EBITDA
10.15
Financial Highlights
Profitability and Income Statement
Profit Margin
5.72%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
20.72B
Net Income Avi to Common (ttm)
1.19B
Diluted EPS (ttm)
17.02
Balance Sheet and Cash Flow
Total Cash (mrq)
1.15B
Total Debt/Equity (mrq)
2.03%
Levered Free Cash Flow (ttm)
--